New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
13:25 EDTILMN, ILMN, ILMN, LMNX, LMNX, LMNX, CPHD, CPHD, CPHD, GNMK, GNMK, GNMK, NSTG, NSTG, NSTG, MYGN, MYGN, MYGN, FLDM, FLDM, FLDM, PACB, PACB, PACB, TMO, TMO, TMO, QGEN, QGEN, QGENLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
News For ILMN;TMO;PACB;FLDM;MYGN;NSTG;GNMK;CPHD;LMNX;QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 15, 2015
08:05 EDTQGENQIAGEN has a conference call hosted by JPMorgan
Subscribe for More Information
07:09 EDTMYGNMyriad Genetics presents clinical data for Prolaris test
Myriad Genetics presented clinical data for its Prolaris test at the 2015 American Urological Association, or AUA, Annual Meeting being held May 15-19 in New Orleans, La. The results highlighted and underscored the significant ability of the Prolaris test to help physicians improve care for men diagnosed with prostate cancer. In this pioneering study, Myriad presented important new clinical validation data that establishes an active surveillance, or AS, threshold for men with localized prostate cancer. Specifically, the AS threshold is a composite of the Prolaris test score and clinicopathologic features. In the validation data featured at AUA, the pre-defined AS threshold was evaluated in 765 conservatively managed men, and the clinical endpoint was 10-year risk of prostate cancer mortality. The results showed that at the AS threshold, the predicted 10-year survival rate of prostate cancer patients was 97%. Conversely, there was a three percent risk of 10-year, prostate-specific mortality. Importantly, however, there were no observed prostate cancer-specific deaths over 10 years among men whose scores fell below the AS threshold. Additionally, a separate analysis of 4,218 patients was performed to determine what percentage of patients who were clinically tested with Prolaris would be candidates for active surveillance based on the validated AS threshold. Of this commercial cohort, 36% qualified for active surveillance based on their clinical features alone. However, when the Prolaris test was added to the clinical risk assessment, 60% of these patients fell below the AS threshold, representing a significant increase in the total number of candidates who may be eligible for active surveillance.
May 14, 2015
16:35 EDTNSTGNanoString announces favorable draft local coverage determination by Palmetto
Subscribe for More Information
May 13, 2015
18:47 EDTMYGNMyriad Genetics to present data from 19 studies at 2015 ASCO meeting
Subscribe for More Information
12:39 EDTTMOOn The Fly: Top stock stories at midday
Subscribe for More Information
May 12, 2015
16:25 EDTTMOOn The Fly: Top stock stories for Tuesday
Stocks began the session deep in negative territory as bond yields in Europe and the U.S. were moving higher. The market saw its lows shortly after the open and soon began to recapture some of its losses. By noon, the losses were cut in half and the Dow made it all the way back to positive ground by the afternoon. Unable to gather any upside momentum, the rally stalled and the averages limped into the close. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' small business optimism rose 1.7 points to 96.9 in April, versus expectations for a 96.0 reading. The JOLTs report showed job openings fell 150K to 4.99M in March, versus expectations for 5.11M openings. The 10-year U.S. Treasury yield climbed at high as 2.37% earlier in the session, which was its highest intraday mark since last November, before easing back by midday. Outside of the U.S., bond yields surged on 10-year notes in Japan, Italy, Spain, Portugal, and Germany. COMPANY NEWS: Shares of AOL (AOL) advanced $7.93, or 18.62%, to $50.52 after Verizon (VZ) agreed to buy the company for $50 per share in a deal valued at $4.4B. Verizon's John Stratton, speaking at the Jefferies 2015 Global TMT Conference, said the AOL deal was primarily about ad technology and Re/code reported that "one scenario" the service has heard about is that Verizon plans to spin off some or all of the content operations it is acquiring by buying AOL, such as the Huffington Post. Yahoo (YHOO) also rose 24c, or 0.55%, to $43.84, as Cantor Fitzgerald analyst Youssef Squali said he now views it as the "last remaining large scale digital media company of its kind." MAJOR MOVERS: Among the notable gainers was Pall Corp. (PLL), which advanced $19.31, or 19.44%, to $118.62 after The Wall Street Journal reported that the company is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers. Also higher was Pain Therapeutics (PTIE), which gained 68c, or 35.05%, to $2.62 after announcing that a study of its lead drug candidate, that is specifically designed to discourage certain common methods of drug tampering and misuse, demonstrated with statistical significance that both intact and chewed Remoxy were less "liked" than immediate-release oxycodone on the two primary endpoints of Drug Liking and Drug High. Among the noteworthy losers was ITT Educational Services (ESI), which plunged $1.75, or 43.53%, to $2.27 after the SEC announced that it had charged the company, along with its CEO and CFO, with fraud. Also lower were shares of NewLink Genetics (NLNK), which dropped $15.59, or 29.9%, to $36.55 after stating that it would continue its flagship IMPRESS trial as planned despite disclosing the FDA did not endorse management's plan to change the statistical analysis plan as defined in the original protocol. INDEXES: The Dow fell 36.94, or 0.2%, to 18,068.23, the Nasdaq slid 17.38, or 0.35%, to 4,976.19, and the S&P 500 dropped 6.21, or 0.29%, to 2,099.12.
14:04 EDTTMOPall Corp. a better strategic fit for Thermo Fisher than Danaher, says Mizuho
Subscribe for More Information
12:34 EDTTMOOn The Fly: Top stock stories at midday
Subscribe for More Information
10:45 EDTTMOAnalyst says Pall deal may spark more life sciences M&A
Subscribe for More Information
09:47 EDTTMOPall Corp. bids due later this week, CNBC's Faber reports
David Faber on CNBC reported that bids for Pall Corp. (PLL) from Danaher (DHR) and Thermo Fisher (TMO) are due later this week. The auction is being led by Goldman Sachs (GS), Faber adds. He notes Danaher is likely going to offer an all-cash bid whereas Thermo Fisher will use up to $2B of equity. Faber said an offer price of $120 per share for Pall is likely the top of the range. The Wall Street Journal reported last night some of these details.
07:46 EDTTMODanaher has upper hand to acquire Pall, says Jefferies
After the Wall Street Journal reported that Pall Corp. (PLL) is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers, Jefferies says it believes Danaher has the upper hand in getting the deal done given its greater relative balance sheet capacity. The firm views both companies as logical buyers for Pall and notes a takeout bid of around $13B implies a share price of $120. The firm has a Buy rating on Pall.
07:31 EDTTMOThermo Fisher acquisition of Pall Corp. could create 'powerhouse,' says UBS
UBS noted Thermo Fisher (TMO) was mentioned in a media report as a possible suitor for Pall Corp. (PLL) and feels if the two combine it could create a bio-production "powerhouse." The firm sees a potential deal as accretive and creating unparalleled scale. UBS also said that, based on current valuation, the potential for a deal is barely being priced into Thermo Fisher shares. UBS reiterated its Buy rating and $160 price target on Thermo Fisher shares.
07:19 EDTNSTGPAM50 included in St. Gallen International Breast Cancer Guidelines
Subscribe for More Information
06:30 EDTTMOPall volatility flat, Danaher, Thermo Fisher to submit final bids, WSJ reports
Subscribe for More Information
May 11, 2015
19:22 EDTTMODanaher, Thermo Fisher to submit final bids for Pall, WSJ says
Danaher (DHR) and Thermo Fisher (TMO) are competing to acquire Pall (PLL), with final bids due later this week, reports The Wall Street Journal, citing people familiar with the matter. A deal could be valued at $13B or more, notes the Journal. Reference Link
18:29 EDTMYGNAffordable Care Act guidance says insurers must cover BRCA1, BRCA2 testing
The United States Department of Labor issued updated Affordable Care Act guidance, which mandates that health insurers must cover testing for breast and ovarian cancer through analysis of the BRCA1 and BRCA2 genes. Myriad (MYGN), Foundation Medicine (FMI), and Genomic Health (GHDX) compete in the genetic testing space. Reference Link
May 8, 2015
16:34 EDTFLDMOn The Fly: Top stock stories for Friday
Subscribe for More Information
12:58 EDTFLDMOn The Fly: Top stock stories at midday
Subscribe for More Information
10:01 EDTFLDMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:46 EDTFLDMFluidigm downgraded to Neutral from Buy at Mizuho
Mizuho analyst Peter Lawson downgraded Fluidigm to Neutral citing a lack of visibility and increased revenue volatility following the company's weaker than expected Q1 results. Lawson cut his price target for shares to $30 from $50.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use